AI accelerates biologic drug design by predicting protein structures and optimizing therapeutic candidates. Machine learning models reduce the traditional multi-year development cycle and lower high failure rates in preclinical testing. This capability transforms how computational biologists and AI developers approach complex therapeutic design problems.
Opening Kapyn…